NO327792B1 - Bifidobakteriumstamme, formulering omfattende nevnte stamme, og anvendelse derav i matprodukter eller medikamenter ved behandling av sykdom. - Google Patents

Bifidobakteriumstamme, formulering omfattende nevnte stamme, og anvendelse derav i matprodukter eller medikamenter ved behandling av sykdom. Download PDF

Info

Publication number: NO327792B1
Authority: NO; Norway
Prior art keywords: strain; formulation according; formulation; treatment; prophylaxis
Prior art date: 1999-01-15

Application number

NO20013429A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013429D0 (no

NO20013429L (no

Inventor

John Kevin Collins

Gerald Christopher O'sullivan

Liam O'mahony

Fergus Shanahan

Original Assignee

Entpr Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-15

Filing date

2001-07-10

Publication date

2009-09-28

1999-01-15 Priority claimed from IE990033A external-priority patent/IE990033A1/en

2001-07-10 Application filed by Entpr Ireland filed Critical Entpr Ireland

2001-07-10 Publication of NO20013429D0 publication Critical patent/NO20013429D0/no

2001-08-27 Publication of NO20013429L publication Critical patent/NO20013429L/no

2009-09-28 Publication of NO327792B1 publication Critical patent/NO327792B1/no

Links

241000186000 Bifidobacterium Species 0.000 title claims abstract description 53
238000011282 treatment Methods 0.000 title claims abstract description 29
239000000203 mixture Substances 0.000 title claims description 54
238000009472 formulation Methods 0.000 title claims description 50
201000010099 disease Diseases 0.000 title claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
239000003814 drug Substances 0.000 title claims description 9
235000013305 food Nutrition 0.000 title claims description 9
229940079593 drug Drugs 0.000 title claims description 5
208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 19
230000002757 inflammatory effect Effects 0.000 claims abstract description 18
238000011321 prophylaxis Methods 0.000 claims abstract description 18
206010028980 Neoplasm Diseases 0.000 claims abstract description 17
201000011510 cancer Diseases 0.000 claims abstract description 11
230000002496 gastric effect Effects 0.000 claims abstract description 9
208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 6
241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 43
239000006041 probiotic Substances 0.000 claims description 32
235000018291 probiotics Nutrition 0.000 claims description 32
230000000529 probiotic effect Effects 0.000 claims description 28
206010012735 Diarrhoea Diseases 0.000 claims description 22
230000001580 bacterial effect Effects 0.000 claims description 12
235000013336 milk Nutrition 0.000 claims description 8
239000008267 milk Substances 0.000 claims description 8
210000004080 milk Anatomy 0.000 claims description 8
230000009885 systemic effect Effects 0.000 claims description 8
235000013618 yogurt Nutrition 0.000 claims description 8
235000013406 prebiotics Nutrition 0.000 claims description 7
108090000623 proteins and genes Proteins 0.000 claims description 7
102000004169 proteins and genes Human genes 0.000 claims description 7
208000023275 Autoimmune disease Diseases 0.000 claims description 6
150000001875 compounds Chemical class 0.000 claims description 6
239000000463 material Substances 0.000 claims description 6
208000011231 Crohn disease Diseases 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
150000002632 lipids Chemical class 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
150000003722 vitamin derivatives Chemical class 0.000 claims description 3
241000193163 Clostridioides difficile Species 0.000 claims description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
208000002389 Pouchitis Diseases 0.000 claims description 2
241000702670 Rotavirus Species 0.000 claims description 2
235000020167 acidified milk Nutrition 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
235000013361 beverage Nutrition 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
235000013351 cheese Nutrition 0.000 claims description 2
206010009887 colitis Diseases 0.000 claims description 2
239000012141 concentrate Substances 0.000 claims description 2
235000015071 dressings Nutrition 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
229930195712 glutamate Natural products 0.000 claims description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
238000002649 immunization Methods 0.000 claims description 2
230000003053 immunization Effects 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
235000010755 mineral Nutrition 0.000 claims description 2
239000002366 mineral element Substances 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
239000011573 trace mineral Substances 0.000 claims description 2
235000013619 trace mineral Nutrition 0.000 claims description 2
210000001035 gastrointestinal tract Anatomy 0.000 abstract description 17
241000282412 Homo Species 0.000 abstract description 8
230000002519 immonomodulatory effect Effects 0.000 abstract description 7
241000699670 Mus sp. Species 0.000 description 41
241000894006 Bacteria Species 0.000 description 34
210000004027 cell Anatomy 0.000 description 27
229920001817 Agar Polymers 0.000 description 20
239000008272 agar Substances 0.000 description 20
230000000694 effects Effects 0.000 description 19
108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 18
102000004127 Cytokines Human genes 0.000 description 17
108090000695 Cytokines Proteins 0.000 description 17
230000012010 growth Effects 0.000 description 16
239000002609 medium Substances 0.000 description 15
238000011579 SCID mouse model Methods 0.000 description 14
210000000941 bile Anatomy 0.000 description 14
210000001519 tissue Anatomy 0.000 description 13
241000186869 Lactobacillus salivarius Species 0.000 description 12
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
210000000936 intestine Anatomy 0.000 description 11
238000000034 method Methods 0.000 description 11
244000005700 microbiome Species 0.000 description 11
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
230000028709 inflammatory response Effects 0.000 description 10
230000004083 survival effect Effects 0.000 description 10
230000008859 change Effects 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
210000004051 gastric juice Anatomy 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
210000000987 immune system Anatomy 0.000 description 8
208000027866 inflammatory disease Diseases 0.000 description 8
230000000770 proinflammatory effect Effects 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
241001608472 Bifidobacterium longum Species 0.000 description 7
108090000174 Interleukin-10 Proteins 0.000 description 7
230000003110 anti-inflammatory effect Effects 0.000 description 7
229940009291 bifidobacterium longum Drugs 0.000 description 7
230000003115 biocidal effect Effects 0.000 description 7
239000000306 component Substances 0.000 description 7
210000002919 epithelial cell Anatomy 0.000 description 7
230000036541 health Effects 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000004580 weight loss Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
102000003814 Interleukin-10 Human genes 0.000 description 6
108090001007 Interleukin-8 Proteins 0.000 description 6
102000004890 Interleukin-8 Human genes 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000003613 bile acid Substances 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
210000001072 colon Anatomy 0.000 description 6
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
229940076144 interleukin-10 Drugs 0.000 description 6
229940096397 interleukin-8 Drugs 0.000 description 6
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 6
239000004310 lactic acid Substances 0.000 description 6
235000014655 lactic acid Nutrition 0.000 description 6
235000016709 nutrition Nutrition 0.000 description 6
230000035764 nutrition Effects 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 5
241000186660 Lactobacillus Species 0.000 description 5
241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 5
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
230000000845 anti-microbial effect Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000000968 intestinal effect Effects 0.000 description 5
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 5
235000015097 nutrients Nutrition 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
208000002491 severe combined immunodeficiency Diseases 0.000 description 5
239000000243 solution Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000000112 colonic effect Effects 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
238000000855 fermentation Methods 0.000 description 4
230000004151 fermentation Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
239000008103 glucose Substances 0.000 description 4
GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 4
230000028993 immune response Effects 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
244000005706 microflora Species 0.000 description 4
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 4
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
239000004380 Cholic acid Substances 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 3
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 3
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
206010035039 Piloerection Diseases 0.000 description 3
241000589516 Pseudomonas Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
241000191940 Staphylococcus Species 0.000 description 3
208000010399 Wasting Syndrome Diseases 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000001142 anti-diarrhea Effects 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229940041514 candida albicans extract Drugs 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 3
229960001091 chenodeoxycholic acid Drugs 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
229960002471 cholic acid Drugs 0.000 description 3
235000019416 cholic acid Nutrition 0.000 description 3
238000003501 co-culture Methods 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
229960003964 deoxycholic acid Drugs 0.000 description 3
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000037406 food intake Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229940039696 lactobacillus Drugs 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 3
230000005371 pilomotor reflex Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
229960001225 rifampicin Drugs 0.000 description 3
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
230000028327 secretion Effects 0.000 description 3
235000020183 skimmed milk Nutrition 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000012138 yeast extract Substances 0.000 description 3
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241000252983 Caecum Species 0.000 description 2
241001112696 Clostridia Species 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010093031 Galactosidases Proteins 0.000 description 2
102000002464 Galactosidases Human genes 0.000 description 2
108010007979 Glycocholic Acid Proteins 0.000 description 2
239000012630 HPLC buffer Substances 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
241000194020 Streptococcus thermophilus Species 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
238000011861 anti-inflammatory therapy Methods 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
229940004120 bifidobacterium infantis Drugs 0.000 description 2
239000003833 bile salt Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004534 cecum Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
229960002433 cysteine Drugs 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
235000013365 dairy product Nutrition 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
229940099347 glycocholic acid Drugs 0.000 description 2
244000005709 gut microbiome Species 0.000 description 2
230000007407 health benefit Effects 0.000 description 2
230000008821 health effect Effects 0.000 description 2
102000052301 human GNAZ Human genes 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
230000008447 perception Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
231100000586 procarcinogen Toxicity 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000006152 selective media Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
241000894007 species Species 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000006433 tumor necrosis factor production Effects 0.000 description 2
230000035899 viability Effects 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
208000007416 Aberrant Crypt Foci Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
241001217014 Bacillus sp. AS Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
108010062877 Bacteriocins Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
241001655328 Bifidobacteriales Species 0.000 description 1
241000186012 Bifidobacterium breve Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
206010012742 Diarrhoea infectious Diseases 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
206010058838 Enterocolitis infectious Diseases 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
108010059881 Lactase Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000001046 Lactobacillus acidophilus Species 0.000 description 1
244000199866 Lactobacillus casei Species 0.000 description 1
235000013958 Lactobacillus casei Nutrition 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
241000935974 Paralichthys dentatus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
241000269978 Pleuronectiformes Species 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010054000 Type II hypersensitivity Diseases 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
210000004082 barrier epithelial cell Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000009045 body homeostasis Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229960002588 cefradine Drugs 0.000 description 1
-1 ceftaxim Chemical compound 0.000 description 1
229960004755 ceftriaxone Drugs 0.000 description 1
VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
229960001668 cefuroxime Drugs 0.000 description 1
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
230000008951 colonic inflammation Effects 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000007799 cork Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
235000014048 cultured milk product Nutrition 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000004890 epithelial barrier function Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229920000912 exopolymer Polymers 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
235000021001 fermented dairy product Nutrition 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000020932 food allergy Nutrition 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
239000005428 food component Substances 0.000 description 1
235000013376 functional food Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
231100000024 genotoxic Toxicity 0.000 description 1
230000001738 genotoxic effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
238000007489 histopathology method Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000007366 host health Effects 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
208000027139 infectious colitis Diseases 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000021995 interleukin-8 production Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940116108 lactase Drugs 0.000 description 1
229940017800 lactobacillus casei Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000012543 microbiological analysis Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229960000210 nalidixic acid Drugs 0.000 description 1
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229960000808 netilmicin Drugs 0.000 description 1
ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000001855 preneoplastic effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000000722 protumoral effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000012048 reactive intermediate Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
230000025053 regulation of cell proliferation Effects 0.000 description 1
230000024833 regulation of cytokine production Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000009962 secretion pathway Effects 0.000 description 1
JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
239000004324 sodium propionate Substances 0.000 description 1
235000010334 sodium propionate Nutrition 0.000 description 1
229960003212 sodium propionate Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
235000019722 synbiotics Nutrition 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
230000008026 type II hypersensitivity Effects 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1
230000002034 xenobiotic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/179—Sakei
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Zoology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Mycology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nutrition Science (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20013429A 1999-01-15 2001-07-10 Bifidobakteriumstamme, formulering omfattende nevnte stamme, og anvendelse derav i matprodukter eller medikamenter ved behandling av sykdom. NO327792B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IE990033A IE990033A1 (en)	1999-01-15	1999-01-15	Bifidobacterium longum infantis in the treatment of inflammatory bowel disease
IE990782		1999-09-20
PCT/IE2000/000008 WO2000042168A2 (en)	1999-01-15	2000-01-17	Bifidobacterium in the treatment of inflammatory disease

Publications (3)

Publication Number	Publication Date
NO20013429D0 NO20013429D0 (no)	2001-07-10
NO20013429L NO20013429L (no)	2001-08-27
NO327792B1 true NO327792B1 (no)	2009-09-28

Family

ID=26320235

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20013429A NO327792B1 (no)	1999-01-15	2001-07-10	Bifidobakteriumstamme, formulering omfattende nevnte stamme, og anvendelse derav i matprodukter eller medikamenter ved behandling av sykdom.
NO20013467A NO20013467L (no)	1999-01-15	2001-07-12	Anvendelse av Lactobacillus salivarius

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20013467A NO20013467L (no)	1999-01-15	2001-07-12	Anvendelse av Lactobacillus salivarius

Country Status (22)

Country	Link
US (13)	US20020006432A1 (zh)
EP (4)	EP1688481A1 (zh)
JP (2)	JP4706016B2 (zh)
CN (3)	CN1245994C (zh)
AT (3)	ATE326012T1 (zh)
AU (3)	AU3071700A (zh)
BR (2)	BRPI0007481B8 (zh)
CA (3)	CA2724287A1 (zh)
DE (3)	DE60035670T2 (zh)
DK (2)	DK1141235T3 (zh)
ES (2)	ES2265331T3 (zh)
HK (1)	HK1044964B (zh)
ID (2)	ID29150A (zh)
IE (1)	IE20000033A1 (zh)
IL (3)	IL144185A0 (zh)
MX (2)	MXPA01007152A (zh)
NO (2)	NO327792B1 (zh)
NZ (2)	NZ529353A (zh)
PT (1)	PT1141235E (zh)
RU (2)	RU2279282C2 (zh)
TR (2)	TR200102058T2 (zh)
WO (3)	WO2000042429A2 (zh)

Families Citing this family (224)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020035071A1 (en) *	1997-07-08	2002-03-21	Josef Pitha	Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en)	1997-07-08	2013-10-22	The Iams Company	Method of maintaining and/or attenuating a decline in quality of life
US20060116330A1 (en) *	1997-07-08	2006-06-01	The Iams Company	Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US7029702B2 (en) *	1998-07-07	2006-04-18	Ritter Natural Sciences Llc	Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
ID29150A (id) *	1999-01-15	2001-08-02	Entpr Ireland Cs	Penggunaan lactobacillus salivarius
EP1212066A4 (en) *	1999-08-09	2004-03-03	Univ Maryland	PROINTESTINAL MATURATION AND ANTI-INFLAMMATORY EFFECTS OF LACTOBACILLUS AS WELL AS PROTEINS, CARBOHYDRATES AND LIPIDS SECRETED BY LACTOBACILLUS
WO2002002138A1 (en) *	2000-07-03	2002-01-10	Probendo Pty Ltd	Treating endotoxemia and related disorders with probiotics
AUPQ899700A0 (en)	2000-07-25	2000-08-17	Borody, Thomas Julius	Probiotic recolonisation therapy
CA2342040C (en) *	2000-09-21	2012-07-10	Kyowa Hakko Kogyo Co., Ltd.	Anaerobic bacterium as a drug for cancer gene therapy
ATE490776T1 (de)	2000-10-06	2010-12-15	Nestec Sa	Verwendung von probiotischen milchsäure- produzierende bakterien zur zum schutz der haut gegen uv-induzierter allergischen reaktionen und entzündungskrankheiten oder immunsuppression
IT1320772B1 (it) *	2000-11-02	2003-12-10	Proge Farm Srl	Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
WO2002061118A1 (fr) *	2001-02-01	2002-08-08	Kabushiki Kaisha Yakult Honsha	Methode d'evaluation de l'acces a l'intestin d'une bacterie bifidus contenue dans un aliment ou une boisson a base de lait fermente
AU2002249531A1 (en) *	2001-04-02	2002-10-28	Alimentary Health Limited	Immunotherapy based on dendritic cells
JP4671384B2 (ja) *	2001-05-15	2011-04-13	雪印乳業株式会社	新規乳酸菌株
EP1264893A1 (en)	2001-06-08	2002-12-11	Teagasc Dairy Products Research Centre	CLA biosynthesis by bifidobacteria
PE20030284A1 (es) *	2001-07-26	2003-05-01	Alimentary Health Ltd	Cepas de bifidobacterium
PE20030274A1 (es)	2001-07-26	2003-05-08	Alimentary Health Ltd	Cepas de lactobacillus salivarius
JP5116194B2 (ja) *	2001-09-04	2013-01-09	株式会社ヤクルト本社	炎症性腸疾患予防治療剤
MXPA04001999A (es) *	2001-09-05	2004-07-16	Vsl Pharmaceuticals Inc	Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia.
GB0124580D0 (en)	2001-10-12	2001-12-05	Univ Reading	New composition
DK1449915T3 (da)	2001-12-07	2006-08-14	Morinaga Milk Industry Co Ltd	Bifidobacterium longum
US6941649B2 (en) *	2002-02-05	2005-09-13	Force10 Networks, Inc.	Method of fabricating a high-layer-count backplane
DE10206995B4 (de) *	2002-02-19	2014-01-02	Orthomol Pharmazeutische Vertriebs Gmbh	Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
WO2003105893A2 (en) *	2002-06-13	2003-12-24	Alimentary Health Limited	Probiotic therapies
US8168170B2 (en)	2002-10-03	2012-05-01	The Procter And Gamble Company	Compositions having an inner core and at least three surrounding layers
IL152127A0 (en)	2002-10-06	2003-05-29	Bio Balance Corp	Probiotic compositions for the treatment of inflammatory bowel disease
US7105336B2 (en) *	2002-10-07	2006-09-12	Biogaia Ab	Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US7179460B2 (en) *	2002-12-05	2007-02-20	Danisco A/S	Bacterial composition and its use
US7740838B2 (en) *	2002-12-05	2010-06-22	Danisco A/S	Bacterial composition and its use
JP2004189672A (ja) *	2002-12-11	2004-07-08	Gen Corp:Kk	抗下痢症組成物
US20040208863A1 (en) *	2003-01-30	2004-10-21	James Versalovic	Anti-inflammatory activity from lactic acid bacteria
SE526711C2 (sv) *	2003-01-31	2005-10-25	Probi Ab	Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20040197304A1 (en)	2003-04-01	2004-10-07	The Procter & Gamble Company And Alimentary Health, Ltd.	Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20040265279A1 (en) *	2003-05-08	2004-12-30	Timothy Dinan	Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
US7749509B2 (en) *	2003-08-29	2010-07-06	Cobb And Company, Llp	Treatment of autism using probiotic composition
US8192733B2 (en)	2003-08-29	2012-06-05	Cobb & Associates	Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7731976B2 (en) *	2003-08-29	2010-06-08	Cobb And Company, Llp	Treatment of irritable bowel syndrome using probiotic composition
US7759105B2 (en) *	2003-08-29	2010-07-20	Cobb & Company, Llp	Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) *	2003-08-29	2006-08-10	Cobb Mark L	Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
GB0323039D0 (en) *	2003-10-01	2003-11-05	Danisco	Method
US20050238631A1 (en) *	2003-12-04	2005-10-27	Steve Burwell	Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria
US20050158294A1 (en) *	2003-12-19	2005-07-21	The Procter & Gamble Company	Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en)	2003-12-19	2010-08-31	The Procter & Gamble Company	Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) *	2003-12-19	2014-11-04	The Iams Company	Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en)	2003-12-19	2014-11-25	The Iams Company	Canine probiotic Lactobacilli
US20050152884A1 (en) *	2003-12-19	2005-07-14	The Procter & Gamble Company	Canine probiotic Bifidobacteria globosum
WO2005072718A1 (ja) *	2004-01-28	2005-08-11	Kurume University	乳清発酵物を含有する医薬組成物
US7862808B2 (en) *	2004-07-01	2011-01-04	Mead Johnson Nutrition Company	Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2006012536A2 (en) *	2004-07-22	2006-02-02	Ritter Andrew J	Methods and compositions for treating lactose intolerance
KR100568036B1 (ko)	2004-08-12	2006-04-07	하남주	장기능 활성화 및 면역기능 강화작용을 하는비피도박테리움 균주 및 이를 함유하는 생균제제
JP2006166829A (ja) *	2004-12-17	2006-06-29	Best Ecology:Kk	アイスサプリメント及びその製造方法
WO2006097949A1 (en) *	2005-03-16	2006-09-21	Actial Farmacêutica, Lda.	Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
ES2640212T3 (es)	2005-04-08	2017-11-02	The Procter & Gamble Company	Uso de bifidobacterias pro bióticas administradas por vía oral para obtener beneficios de belleza en seres humanos
AU2011205121B2 (en) *	2005-04-08	2012-07-05	Alimentary Health Ltd	Method of use of orally administered probiotic bifidobacteria for human beauty benefits
US20060228448A1 (en)	2005-04-11	2006-10-12	The Iams Company	Pet food compositions comprising two components
US7303745B2 (en) *	2005-04-15	2007-12-04	Bristol-Myers Squibb Company	Method for preventing or treating the development of respiratory allergies
AU2006253006B8 (en)	2005-05-31	2011-09-15	Alimentary Health Ltd	Feline probiotic Lactobacilli
AU2006253007B2 (en) *	2005-05-31	2012-12-20	Alimentary Health Ltd	Feline probiotic Bifidobacteria
BRPI0613805A2 (pt) *	2005-07-20	2011-02-15	Unilever Nv	método de preparação de um produto comestìvel e produto comestìvel
ITMI20051510A1 (it) *	2005-08-02	2007-02-03	Proge Farm Srl	Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti
RU2297835C1 (ru) *	2005-09-26	2007-04-27	Закрытое акционерное общество "Партнер"	Препарат для лечения неинфекционных воспалительных болезней кишечника
WO2007038466A2 (en) *	2005-09-27	2007-04-05	Cobb & Company	Treatment of bipolar disorder utilizing anti-fungal compositions
US7943328B1 (en)	2006-03-03	2011-05-17	Prometheus Laboratories Inc.	Method and system for assisting in diagnosing irritable bowel syndrome
ATE552734T1 (de) *	2006-03-31	2012-04-15	Morinaga Milk Industry Co Ltd	Verfahren zur herstellung des interleukin- produktionsreglers
WO2007133188A1 (en) *	2006-05-01	2007-11-22	Cobb & Company, Llp	Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US20080085524A1 (en)	2006-08-15	2008-04-10	Prometheus Laboratories Inc.	Methods for diagnosing irritable bowel syndrome
WO2008053444A2 (en)	2006-11-01	2008-05-08	The Procter & Gamble Company	Treating a respiratory condition with bifidobacterium
US7964238B2 (en) *	2007-01-29	2011-06-21	Guardian Industries Corp.	Method of making coated article including ion beam treatment of metal oxide protective film
MX2009008166A (es)	2007-02-01	2009-08-12	Iams Company	Metodo para disminuir la inflamacion y estres en un mamifero usando antimetabolitos de glucosa, aguacate o extractos de aguacate.
CN101678052A (zh) *	2007-02-22	2010-03-24	于尔根·施赖岑米尔	用于在人中预防、抑制或消除变态反应的益生性革兰氏阳性细菌
ES2381232T3 (es) *	2007-02-28	2012-05-24	Mead Johnson Nutrition Company	Procedimiento para el tratamiento o la prevención de la inflamación sistémica
CN101636173A (zh) *	2007-03-27	2010-01-27	宝洁公司	施用益生菌剂的方法及试剂盒
GB2465051B (en) *	2007-03-28	2012-01-25	Alimentary Health Ltd	Probiotic bifidobacterium strains
WO2008117267A2 (en) *	2007-03-28	2008-10-02	Alimentary Health Limited	Probiotic bifidobacterium strains
CN101835806B (zh)	2007-05-04	2012-11-07	营养健康有限公司	外泌多糖
EP2179028B1 (en)	2007-06-27	2014-08-13	Laboratorios Ordesa, S.l.	A novel strain of bifidobacterium and active peptides against rotavirus infections
JP2009057346A (ja) *	2007-09-03	2009-03-19	Kirin Holdings Co Ltd	免疫バランス調節用組成物
FR2921795B1 (fr) *	2007-10-03	2011-04-29	Gervais Danone Sa	Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
US20100310522A1 (en) *	2007-11-26	2010-12-09	Plant Bioscience Limited	Novel Polypeptides Having Endolysin Activity and Uses Thereof
US20110223248A1 (en) *	2007-12-12	2011-09-15	Ritter Pharmaceuticals, Inc.	Methods and compositions for treating lactose intolerance
PL2072053T3 (pl) *	2007-12-21	2013-02-28	Gervais Danone Sa	Sposób zmniejszania obwodu brzucha przez podawanie bakterii bifidobacterium
ES2343499B1 (es) *	2007-12-24	2011-06-10	Consejo Superior De Investigaciones Cientificas	Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EP2110028A1 (en)	2008-04-15	2009-10-21	Nestec S.A.	Bifidobacterium longum and hippocampal BDNF expression
US9771199B2 (en)	2008-07-07	2017-09-26	Mars, Incorporated	Probiotic supplement, process for making, and packaging
US20110189148A1 (en) *	2008-06-25	2011-08-04	Ritter Pharmaceuticals, Inc.	Lactose compositions with decreased lactose content
US9232813B2 (en) *	2008-07-07	2016-01-12	The Iams Company	Probiotic supplement, process for making, and packaging
DK2318513T3 (da) *	2008-07-11	2012-10-22	Chr Hansen As	Ny probiotisk bifidobacterium longum
RU2453320C2 (ru) *	2008-08-05	2012-06-20	Виктор Владимирович Чалов	Композиция для перорального применения, содержащая непатогенные микроорганизмы, обладающая способностью нормализовать микрофлору кишечника (варианты)
EP2334196B1 (en) *	2008-09-11	2012-08-29	The IAMS Company	Animal feed kibble with protein-based core and related methods
US20100074870A1 (en) *	2008-09-19	2010-03-25	Bristol-Myers Squibb Company	Probiotic infant products
KR101057357B1 (ko)	2008-09-22	2011-08-17	광주과학기술원	유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
MX349706B (es) *	2008-11-11	2017-08-09	Alimentary Health Ltd	Bifidobacterium longum.
CA2752800C (en)	2009-02-24	2017-12-05	Ritter Pharmaceuticals, Inc.	Prebiotic formulations and methods of use
GB0908949D0 (en)	2009-05-26	2009-07-01	Plant Bioscience Ltd	Novel polypeptides having endolysin activity and uses thereof
US20100330151A1 (en)	2009-06-25	2010-12-30	Mary Elaine Freeland	Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
US10104903B2 (en)	2009-07-31	2018-10-23	Mars, Incorporated	Animal food and its appearance
US20110027412A1 (en)	2009-07-31	2011-02-03	Kris Eugene Spence	Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
DK2289527T3 (en)	2009-08-25	2018-04-23	Nestec Sa	BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISEASES
JP5690270B2 (ja) *	2009-09-02	2015-03-25	京都府公立大学法人	乳酸菌由来のｒｎａを有効成分とする組成物
JP2013507394A (ja) *	2009-10-09	2013-03-04	プロセラインコーポレイテッド	自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
CN103037875B (zh) *	2009-11-11	2014-11-05	食物营养健康有限公司	双歧杆菌菌株
EP2498789B1 (en) *	2009-11-11	2016-06-22	Alimentary Health Limited	Probiotic bifidobacterium strain
ES2437940T3 (es) *	2010-01-28	2014-01-15	Ab-Biotics S.A.	Composición probiótica para uso en el tratamiento de la inflamación del intestino
SI3564357T1 (sl)	2010-02-01	2022-09-30	Rebiotix, Inc.	Bakterioterapija Clostridium Difficile colitisa
FR2955774A1 (fr)	2010-02-02	2011-08-05	Aragan	Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
WO2011118060A1 (ja) *	2010-03-26	2011-09-29	株式会社明治	腸管免疫の抑制剤のスクリーニング方法
RU2451740C2 (ru) *	2010-04-26	2012-05-27	Татьяна Александровна Левченко	ШТАММ Bifidobacterium longum АБД-7, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2451741C2 (ru) *	2010-04-26	2012-05-27	Татьяна Александровна Левченко	ШТАММ Bifidobacterium longum АБД-3, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
EP2563372A4 (en)	2010-04-28	2013-10-02	Ritter Pharmaceuticals Inc	PREBIOTIC FORMULATIONS AND METHODS OF USE
WO2011148219A1 (en) *	2010-05-28	2011-12-01	Compagnie Gervais Danone	Probiotic strains for use in improving the enteric nervous system
CN102269858A (zh)	2010-06-02	2011-12-07	北京智朗芯光科技有限公司	自动聚焦系统和自动聚焦方法
WO2011151941A1 (ja)	2010-06-04	2011-12-08	国立大学法人東京大学	制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
FR2962045B1 (fr) *	2010-07-05	2012-08-17	Bifinove	Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
RU2013109251A (ru)	2010-08-04	2014-09-10	Томас Джулиус БОРОДИ	Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки
RU2593716C2 (ru) *	2010-11-11	2016-08-10	Нестек С.А.	Замороженные кондитерские изделия, содержащие пробиотические микроорганизмы
DK2481299T3 (en)	2011-01-31	2017-02-06	Dr Fischer Gesundheitsprodukte Gmbh	BIFIDOBACTERIUM BIFIDUM STREAMS FOR USE IN GASTROINTESTINAL DISEASES
ES2636439T3 (es)	2011-03-09	2017-10-05	Regents Of The University Of Minnesota	Composiciones y métodos para el trasplante de microbiota de colon
WO2012140636A1 (en)	2011-04-11	2012-10-18	Alimentary Health Limited	A probiotic formulation
RU2460777C1 (ru) *	2011-04-21	2012-09-10	Общество с ограниченной ответственностью "Бифилюкс"	Штамм bifidobacterium longum, используемый для получения бифидосодержащей продукции
GB201112091D0 (en)	2011-07-14	2011-08-31	Gt Biolog Ltd	Bacterial strains isolated from pigs
GB201117313D0 (en)	2011-10-07	2011-11-16	Gt Biolog Ltd	Bacterium for use in medicine
KR101355440B1 (ko)	2011-10-26	2014-02-05	주식회사한국야쿠르트	류마티스 관절염 예방 효능을 갖는 락토바실러스 헬베티쿠스 에이취와이7801 및 이를 유효성분으로 함유하는 제품
CN103131647B (zh) *	2011-11-29	2017-06-27	上海上药信谊药厂有限公司	婴儿双歧杆菌及其制剂
EP2785828B1 (en)	2011-12-01	2020-04-08	The University of Tokyo	Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
JP5468183B2 (ja) *	2011-12-28	2014-04-09	株式会社山田養蜂場本社	ＩｇＡ産生促進作用を有する新規乳酸菌及びその用途
WO2013107913A1 (en)	2012-01-19	2013-07-25	University College Cork - National University Of Ireland, Cork	Gaba-producing culturable bacteria derived from the human gastrointestinal tract
US9173910B2 (en)	2012-02-29	2015-11-03	The General Hospital Corporation	Compositions of microbiota and methods related thereto
DK2830599T3 (en)	2012-03-29	2018-10-08	Therabiome Llc	SITE-SPECIFIC GASTROINTESTINAL ORAL VACCINE FORMS WITH EFFECTS ON ILEUM AND APPENDIX
US9719144B2 (en)	2012-05-25	2017-08-01	Arizona Board Of Regents	Microbiome markers and therapies for autism spectrum disorders
JP2015526469A (ja)	2012-08-20	2015-09-10	ボリス, マルコシアンMarkosian, Boris	癌に対する胎盤ワクチン接種療法
FR2999601B1 (fr) *	2012-12-17	2015-01-30	Urgo Lab	Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
EP2968187A4 (en)	2013-03-14	2016-08-17	Therabiome Llc	TARGETED ADMINISTRATION OF PROBIOTIC ORGANISMS AND / OR THERAPEUTIC AGENTS IN THE GASTROINTESTINAL TRACT
KR101434220B1 (ko) *	2013-03-26	2014-08-28	삼육대학교산학협력단	다제내성균에 대한 저해 활성을 갖는 신규 유산균
GB201306536D0 (en)	2013-04-10	2013-05-22	Gt Biolog Ltd	Polypeptide and immune modulation
US9511100B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102291174B1 (ko)	2013-06-05	2021-08-18	리바이오틱스, 인코퍼레이티드	미생물상 복원 요법(mrt), 조성물 및 제조방법
US9782445B2 (en)	2013-06-05	2017-10-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en)	2013-06-05	2019-08-20	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en)	2013-06-05	2017-07-04	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10633714B2 (en)	2013-07-21	2020-04-28	Pendulum Therapeutics, Inc.	Methods and systems for microbiome characterization, monitoring and treatment
WO2015112292A1 (en)	2014-01-24	2015-07-30	The Procter & Gamble Company	Web comprising a microorganism-containing fibrous element and method for making same
CN106414709A (zh)	2014-01-24	2017-02-15	宝洁公司	包含微生物的长丝及其制备方法
US20150209468A1 (en)	2014-01-24	2015-07-30	The Procter & Gamble Company	Hygiene article containing microorganism
GB2551642B (en)	2014-10-31	2020-09-23	Pendulum Therapeutics Inc	Methods and compositions relating to microbial treatment and diagnosis of disorders
BR112017012299B1 (pt)	2014-12-23	2022-04-12	4D Pharma Research Limited	Bacterioide thetaiotaomicron, seu uso, composição, suplemento nutricional, gênero alimentício, produto alimentar, suplemento dietético ou aditivo alimentar e processo para produção destes
WO2016102951A1 (en)	2014-12-23	2016-06-30	4D Pharma Research Limited	Pirin polypeptide and immune modulation
EP3256004A1 (en)	2015-02-13	2017-12-20	Mars, Incorporated	Pet food feeding system
CN107529789A (zh)	2015-04-28	2018-01-02	马斯公司	制备灭菌湿宠物食品的方法
KR20180026376A (ko)	2015-05-14	2018-03-12	크레스토보 홀딩스 엘엘씨	대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
CA2986485A1 (en)	2015-05-22	2016-12-01	Arizona Board Of Regents On Behalf Of Arizona State University	Methods for treating autism spectrum disorder and associated symptoms
WO2016196605A1 (en)	2015-06-01	2016-12-08	The University Of Chicago	Treatment of cancer by manipulation of commensal microflora
US20160354507A1 (en)	2015-06-07	2016-12-08	The Procter & Gamble Company	Article of commerce containing absorbent article
US10799539B2 (en)	2015-06-09	2020-10-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102175829B1 (ko)	2015-06-09	2020-11-06	리바이오틱스, 인코퍼레이티드	미생물상 복원 치료(ｍｒｔ) 조성물 및 제조 방법
US10905726B2 (en)	2015-06-09	2021-02-02	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en)	2015-06-09	2020-11-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA41060B1 (fr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
HUE058252T2 (hu)	2015-06-15	2022-07-28	4D Pharma Res Ltd	Baktériumtörzseket tartalmazó készítmények
MA41010B1 (fr)	2015-06-15	2020-01-31	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
SI3307288T1 (sl)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Spojine, ki vsebujejo bakterijske seve
SG10201912323VA (en)	2015-06-15	2020-02-27	4D Pharma Res Ltd	Compositions comprising bacterial strains
US20170020750A1 (en)	2015-07-23	2017-01-26	The Procter & Gamble Company	Patch containing microorganism
EP3341081B1 (en)	2015-08-27	2020-11-11	PrecisionBiotics Group Limited	Use of bifidobacterium longum and an exopolysaccharide produced thereby
CN108135946A (zh)	2015-08-27	2018-06-08	宝洁公司	长双歧杆菌
EP3359171B1 (en)	2015-10-05	2023-07-05	Schweizerisches Forschungsinstitut für Hochgebirgsklima und Medizin in Davos	Use of akkermansia muciniphila for treating inflammatory conditions
MA41013A (fr)	2015-11-20	2017-08-30	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
GB201520497D0 (en)	2015-11-20	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201520638D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201520631D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201612191D0 (en)	2016-07-13	2016-08-24	4D Pharma Plc	Compositions comprising bacterial strains
PL3313423T3 (pl)	2016-03-04	2019-09-30	4D Pharma Plc	Kompozycje zawierające szczepy bakteryjne blautia do leczenia nadwrażliwości trzewnej
EP3950592A1 (en) *	2016-03-04	2022-02-09	California Institute of Technology	New germanosilicate composition and method of preparing the same
RU2659240C2 (ru) *	2016-05-23	2018-06-29	федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ)	Способ получения функционального продукта питания для реабилитации онкологических больных
US20170360848A1 (en)	2016-06-15	2017-12-21	Arizona Board Of Regents On Behalf Of Arizona State University	Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en)	2016-07-01	2020-12-01	Regents Of The University Of Minnesota	Compositions and methods for C. difficile treatment
TWI802545B (zh)	2016-07-13	2023-05-21	英商４Ｄ製藥有限公司	包含細菌菌株之組合物
US20180036352A1 (en)	2016-08-03	2018-02-08	Crestovo Holdings Llc	Methods for treating ulcerative colitis
US11026978B2 (en)	2016-10-11	2021-06-08	Finch Therapeutics Holdings Llc	Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en)	2016-10-11	2018-10-09	Crestovo Holdings Llc	Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en)	2016-10-11	2022-01-04	Finch Therapeutics Holdings Llc	Compositions and method for treating primary sclerosing cholangitis and related disorders
IT201600121481A1 (it) *	2016-11-30	2018-05-30	Sintal Dietetics Srl	L. salivarius sgl03: attività probiotiche e produzione di proteine antimicrobiche
GB201621123D0 (en)	2016-12-12	2017-01-25	4D Pharma Plc	Compositions comprising bacterial strains
CN107043705A (zh) *	2016-12-30	2017-08-15	大连医科大学	用于建立临床营养菌种资源库的益生菌筛选方法
MX2019009079A (es) *	2017-01-31	2019-09-26	Univ Industry Cooperation Group Kyung Hee Univ	Nuevas bacterias acido lacticas y usos de las mismas.
EP3589726A1 (en)	2017-02-28	2020-01-08	Alimentary Health Limited	Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
WO2018187464A1 (en)	2017-04-05	2018-10-11	Crestovo Holdings Llc	Compositions and methods for treating diverticulitis and related disorders
WO2018187467A1 (en)	2017-04-05	2018-10-11	Crestovo Holdings Llc	Compositions and methods for treating parkinson's disease (pd) and related disorders
TW201907928A (zh)	2017-05-22	2019-03-01	英商4D製藥研究有限公司	包含細菌品系之組成物
TW201907931A (zh)	2017-05-24	2019-03-01	英商4D製藥研究有限公司	包含細菌菌株之組合物
AU2018272048B2 (en)	2017-05-26	2024-04-04	Finch Therapeutics Holdings Llc	Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
MA49373B1 (fr)	2017-06-14	2021-02-26	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
KR102519483B1 (ko)	2017-06-14	2023-04-10	4디 파마 리서치 리미티드	메가스파에라 (megasphera) 속의 세균 균주를 포함하는 조성물 및 이들의 용도
ES2855701T3 (es)	2017-06-14	2021-09-24	4D Pharma Res Ltd	Composiciones que comprenden cepas bacterianas
JP7254786B2 (ja)	2017-07-05	2023-04-10	エヴェロバイオサイエンシズ，インコーポレーテッド	ビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍａｎｉｍａｌｉｓｓｓｐ．ｌａｃｔｉｓ）を用いて癌を処置するための組成物及び方法
EP3664823B1 (en) *	2017-08-07	2024-06-05	Finch Therapeutics Holdings LLC	Composition for use in preventing or treating an enterococcal blood stream infection
EP3675882A4 (en)	2017-08-30	2021-07-28	Pendulum Therapeutics, Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
RU2665173C1 (ru) *	2017-09-18	2018-08-28	Федеральное государственное бюджетное образовательное учреждение высшего образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ профилактики атопического дерматита у младенцев путем модуляции микробного механизма гистаминообразования
US20200338144A1 (en) *	2017-11-01	2020-10-29	Biofermin Pharmaceutical Co., Ltd.	Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
WO2019103198A1 (ko)	2017-11-24	2019-05-31	주식회사 고바이오랩	락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
EP3517119B1 (en)	2018-01-26	2021-08-11	Probisearch, S.L.U.	Composition comprising new lactobacillus salivarius strain and method for the prevention and treatment of otitis and upper respiratory infections
CN112074193A (zh) *	2018-01-29	2020-12-11	精密生物集团有限公司	一种用于预防和治疗肠易激综合征的组合产品
US20190298783A1 (en) *	2018-03-28	2019-10-03	Morinaga Milk Industry Co., Ltd.	Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress
RU2670054C1 (ru) *	2018-04-24	2018-10-17	Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук	Штамм бактерий Bifidobacterium bifidum ICIS-310 - продуцент ингибитора провоспалительного цитокина INF-γ
EP3792342A4 (en)	2018-05-09	2022-01-12	Kobiolabs, Inc.	LACTOBACILLUS PARACASEI STRAIN AND ITS USE
CN113151036B (zh) *	2018-05-11	2024-08-23	韩国亿诺生物有限公司	具有预防或治疗癌症的效果的新型菌株
WO2019226003A1 (ko)	2018-05-23	2019-11-28	주식회사 고바이오랩	락토바실러스 가세리 kbl697 균주 및 그 용도
WO2019227414A1 (zh) *	2018-05-31	2019-12-05	深圳华大生命科学研究院	一种组合物及其应用
US11166990B2 (en)	2018-07-13	2021-11-09	Finch Therapeutics Holdings Llc	Methods and compositions for treating ulcerative colitis
CN109486700A (zh) *	2018-08-31	2019-03-19	石家庄君乐宝乳业有限公司	副干酪乳杆菌n1115预防结肠炎的应用及相应的益生菌粉、应用
CN113164527A (zh)	2018-09-27	2021-07-23	芬奇治疗控股有限责任公司	用于治疗癫痫和相关障碍的组合物和方法
ES2752798B2 (es) *	2018-10-05	2020-08-12	Consejo Superior Investigacion	Cepa de Bifidobacterium longum sub. infantis y uso de la misma
KR102074445B1 (ko) *	2018-12-12	2020-02-06	주식회사 비피도	류마티스관절염 개선, 예방 또는 치료를 위한 비피도박테리움 롱검 rapo 균주 및 이를 포함하는 조성물
US20220273733A1 (en) *	2019-07-26	2022-09-01	Evolve Biosystems, Inc.	Nutritive compositions with bioactive proteins
KR102224072B1 (ko) *	2019-08-19	2021-03-10	주식회사 빙그레	면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도
CN110547915A (zh) *	2019-08-29	2019-12-10	云南白药清逸堂实业有限公司	应用益生菌的卫生棉制品及其制备方法
CN110452860A (zh) *	2019-09-24	2019-11-15	厦门大学	一种唾液链球菌及其在治疗炎症性肠病药物中的应用
US20230106819A1 (en)	2020-03-13	2023-04-06	Precisionbiotics Group Limited	Bifidobacterium longum
TWI748395B (zh) *	2020-03-31	2021-12-01	豐華生物科技股份有限公司	緩解過敏以及提升運動表現之組合物及其用途
CN113943681B (zh) *	2020-11-12	2023-07-04	江南大学	一株降低炎症反应且具有缓解便秘作用的长双歧杆菌
KR102307603B1 (ko) *	2020-11-13	2021-10-05	주식회사 비피도	비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물
CN114317310B (zh) *	2021-03-31	2023-09-22	江苏蓝泽生物科技有限公司	一种抗过敏的婴儿双歧杆菌制剂及其制备方法
CN114558037B (zh) *	2022-02-24	2023-08-15	同济大学	Akk和ls在制备提高认识水平的抗衰老产品中的应用
CN115725456B (zh) *	2022-10-11	2024-06-21	四川大学	一种唾液乳杆菌及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6038372B2 (ja)	1975-04-09	1985-08-31	日清製粉株式会社	犬の下痢予防および治療方法
JPS55113718A (en) *	1979-02-27	1980-09-02	Yakult Honsha Co Ltd	Antitumor agent
US4435389A (en) *	1980-07-07	1984-03-06	Kabushiki Kaisha Yakult Honsha	Composition for promoting growth of bifidobacteria
JPS59118712A (ja) *	1982-12-27	1984-07-09	Morinaga Milk Ind Co Ltd	抗腫瘍剤及びその製造法
US4678773A (en) *	1983-08-26	1987-07-07	Chugai Seiyaku Kabushiki Kaisha	Antitumor agent
US4839281A (en) *	1985-04-17	1989-06-13	New England Medical Center Hospitals, Inc.	Lactobacillus strains and methods of selection
JPH0696538B2 (ja) *	1985-12-19	1994-11-30	株式会社アドバンス	抗発癌剤
JPS63196521A (ja) *	1987-02-10	1988-08-15	Yakult Honsha Co Ltd	腫瘍細胞障害性因子誘起剤
US5352586A (en) *	1987-05-01	1994-10-04	Biogaia Ab	Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
DK686187D0 (da)	1987-12-23	1987-12-23	Hansens Chr Bio Syst	Veterinaert praeparat
US5443826A (en) *	1988-08-02	1995-08-22	Borody; Thomas J.	Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
CA1333564C (en)	1988-08-02	1994-12-20	Thomas Julius Borody	Treatment of gastro-intestinal disorders
SE8900546D0 (sv)	1989-02-17	1989-02-17	Bioinvent Int Ab	Medel foer inhibering av patogeners adhesion tillvaext och /eller oeverlevnad
NZ232512A (en)	1989-02-21	1993-09-27	Viskase Corp	Compositions and firms containing antibacterial agents, methods of treating foodstuffs therewith
JP2932283B2 (ja) *	1989-07-14	1999-08-09	雪印乳業株式会社	ビフィズス菌を含有する醗酵乳の製造方法
GB9107305D0 (en)	1991-04-08	1991-05-22	Unilever Plc	Probiotic
US5413785A (en) *	1993-01-27	1995-05-09	New England Deaconess Hospital Corp.	Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
RU2031586C1 (ru) *	1993-02-05	1995-03-27	Тамара Георгиевна Извекова	Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
JPH0782158A (ja) *	1993-09-16	1995-03-28	Yakult Honsha Co Ltd	抗腫瘍剤
JP3623977B2 (ja) *	1993-10-29	2005-02-23	明治乳業株式会社	潰瘍性大腸炎治療剤
JPH07265064A (ja) *	1993-11-23	1995-10-17	Taketoshi Yamada	腸内細菌叢改善組成物
EP0727216B1 (en) *	1994-07-15	2003-05-28	TAIYO KAGAKU Co., LTD.	Medicinal composition containing sialic acid derivative
JP2780154B2 (ja) *	1995-02-17	1998-07-30	株式会社ヤクルト本社	ヨーグルト
JPH092959A (ja) *	1995-06-16	1997-01-07	Yakult Honsha Co Ltd	ＩｇＥ抗体産生抑制剤および抗アレルギー剤
RU2091075C1 (ru)	1995-06-28	1997-09-27	Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов	Комплексный бактериальный препарат для лечения и профилактики желудочно-кишечных заболеваний животных
JP4021951B2 (ja) *	1996-03-01	2007-12-12	わかもと製薬株式会社	乳酸菌を有効成分とする抗胃炎剤、抗潰瘍剤および醗酵食品
JPH09241179A (ja) *	1996-03-01	1997-09-16	Meiji Seika Kaisha Ltd	ビフィドバクテリウム属菌由来の水溶性免疫賦活物質およびその精製法
US5902578A (en)	1996-03-25	1999-05-11	Abbott Laboratories	Method and formula for the prevention of diarrhea
TW357191B (en) *	1996-06-04	1999-05-01	Food Industry Development Res Institute	Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
IT1288119B1 (it) *	1996-06-28	1998-09-10	Renata Maria Anna Ve Cavaliere	Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
CA2280704A1 (en) *	1997-02-11	1998-08-13	University College Cork	Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom
US6132710A (en) *	1997-03-17	2000-10-17	Probiotix, Inc.	Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
RU2109054C1 (ru)	1997-04-01	1998-04-20	Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского	Консорциум бифидобактерий bifidobacterium bifidum 791, b. longum b 379 m, b. breve 79-119, b. infantis 73-15, b. adolescentis г 7513 для приготовления кисломолочных, неферментированных пищевых продуктов и бактерийных препаратов
CN1178703A (zh) *	1997-08-06	1998-04-15	北京东方百信生物技术有限公司	幼儿胃肠安制剂及其生产工艺
EP0904784A1 (en)	1997-09-22	1999-03-31	N.V. Nutricia	Probiotic nutritional preparation
US5902743A (en) *	1998-03-20	1999-05-11	Wisconsin Alumni Research Foundation	Probiotic bifidobacterium strain
FI980782A (fi)	1998-04-03	1999-10-04	Timo Korhonen	Epiteelisoluihin sitoutuva proteiinialue ja sitä koodaava DNA-sekvenssi
US6368591B2 (en) *	1998-05-15	2002-04-09	Shanghai Sine Pharmaceutical Corporation Ltd.	Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
WO1999062348A1 (en)	1998-05-29	1999-12-09	Enterprise Ireland (Trading As Bioresearch Ireland)	Process for the manufacture of probiotic cheese
ES2214049T3 (es) *	1998-10-20	2004-09-01	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Uso de una cepa de lactococcus productora de citoquinas para tratar colitis.
ID29150A (id)	1999-01-15	2001-08-02	Entpr Ireland Cs	Penggunaan lactobacillus salivarius
AUPQ415899A0 (en)	1999-11-19	1999-12-16	Vasse Research Institute Pty Ltd	Compositions for and methods of treatment of allergic diseases
JP3944076B2 (ja)	2000-08-25	2007-07-11	わかもと製薬株式会社	乳酸菌含有プロバイオティクス製品
US6618973B2 (en) *	2001-05-15	2003-09-16	Ned H. Nelson	Banner holder

2000
- 2000-01-15 ID IDW00200101531A patent/ID29150A/id unknown
- 2000-01-17 CA CA2724287A patent/CA2724287A1/en not_active Abandoned
- 2000-01-17 AT AT00900790T patent/ATE326012T1/de not_active IP Right Cessation
- 2000-01-17 CN CNB00802829XA patent/CN1245994C/zh not_active Expired - Fee Related
- 2000-01-17 MX MXPA01007152A patent/MXPA01007152A/es active IP Right Grant
- 2000-01-17 ES ES00900789T patent/ES2265331T3/es not_active Expired - Lifetime
- 2000-01-17 CN CNB008040893A patent/CN100552016C/zh not_active Expired - Lifetime
- 2000-01-17 DE DE60035670T patent/DE60035670T2/de not_active Expired - Lifetime
- 2000-01-17 AT AT00900788T patent/ATE367820T1/de not_active IP Right Cessation
- 2000-01-17 BR BRPI0007481 patent/BRPI0007481B8/pt not_active IP Right Cessation
- 2000-01-17 NZ NZ529353A patent/NZ529353A/en not_active IP Right Cessation
- 2000-01-17 TR TR2001/02058T patent/TR200102058T2/xx unknown
- 2000-01-17 ES ES00900788T patent/ES2290008T3/es not_active Expired - Lifetime
- 2000-01-17 JP JP2000593725A patent/JP4706016B2/ja not_active Expired - Lifetime
- 2000-01-17 AU AU30717/00A patent/AU3071700A/en not_active Abandoned
- 2000-01-17 MX MXPA01007144A patent/MXPA01007144A/es not_active Application Discontinuation
- 2000-01-17 JP JP2000593317A patent/JP2004502633A/ja active Pending
- 2000-01-17 DK DK00900789T patent/DK1141235T3/da active
- 2000-01-17 AU AU30716/00A patent/AU779405B2/en not_active Expired
- 2000-01-17 BR BR0007550-7A patent/BR0007550A/pt not_active Application Discontinuation
- 2000-01-17 DK DK00900788T patent/DK1143985T3/da active
- 2000-01-17 PT PT00900789T patent/PT1141235E/pt unknown
- 2000-01-17 WO PCT/IE2000/000009 patent/WO2000042429A2/en active IP Right Grant
- 2000-01-17 EP EP06009910A patent/EP1688481A1/en not_active Withdrawn
- 2000-01-17 EP EP00900788A patent/EP1143985B1/en not_active Expired - Lifetime
- 2000-01-17 IL IL14418500A patent/IL144185A0/xx unknown
- 2000-01-17 AU AU30715/00A patent/AU3071500A/en not_active Abandoned
- 2000-01-17 WO PCT/IE2000/000008 patent/WO2000042168A2/en active IP Right Grant
- 2000-01-17 DE DE60028003T patent/DE60028003T2/de not_active Expired - Lifetime
- 2000-01-17 EP EP00900790A patent/EP1145001B1/en not_active Expired - Lifetime
- 2000-01-17 WO PCT/IE2000/000007 patent/WO2000041707A2/en active IP Right Grant
- 2000-01-17 CN CN2009101668989A patent/CN101744841B/zh not_active Expired - Lifetime
- 2000-01-17 IL IL14418400A patent/IL144184A0/xx unknown
- 2000-01-17 NZ NZ530273A patent/NZ530273A/en not_active IP Right Cessation
- 2000-01-17 RU RU2001119057/13A patent/RU2279282C2/ru not_active IP Right Cessation
- 2000-01-17 EP EP00900789A patent/EP1141235B1/en not_active Expired - Lifetime
- 2000-01-17 CA CA002360243A patent/CA2360243A1/en not_active Abandoned
- 2000-01-17 IE IE20000033A patent/IE20000033A1/en not_active IP Right Cessation
- 2000-01-17 CA CA2359334A patent/CA2359334C/en not_active Expired - Lifetime
- 2000-01-17 RU RU2001119046/13A patent/RU2308483C2/ru active
- 2000-01-17 DE DE60027866T patent/DE60027866D1/de not_active Expired - Lifetime
- 2000-01-17 ID IDW00200101530A patent/ID30449A/id unknown
- 2000-01-17 AT AT00900789T patent/ATE326525T1/de active
- 2000-01-17 TR TR2001/02059T patent/TR200102059T2/xx unknown
2001
- 2001-07-05 IL IL144185A patent/IL144185A/en not_active IP Right Cessation
- 2001-07-10 NO NO20013429A patent/NO327792B1/no not_active IP Right Cessation
- 2001-07-12 NO NO20013467A patent/NO20013467L/no unknown
- 2001-07-13 US US09/903,681 patent/US20020006432A1/en not_active Abandoned
2002
- 2002-09-06 HK HK02106566.9A patent/HK1044964B/zh not_active IP Right Cessation
- 2002-09-12 US US10/241,797 patent/US20030166257A1/en not_active Abandoned
2003
- 2003-03-03 US US10/376,602 patent/US20030170217A1/en not_active Abandoned
- 2003-03-17 US US10/388,652 patent/US20030215467A1/en not_active Abandoned
2004
- 2004-02-23 US US10/783,020 patent/US7195906B2/en not_active Expired - Lifetime
- 2004-03-19 US US10/804,223 patent/US20050084482A1/en not_active Abandoned
- 2004-10-04 US US10/956,330 patent/US20050214272A1/en not_active Abandoned
- 2004-10-29 US US10/975,353 patent/US20060002908A1/en not_active Abandoned
2005
- 2005-12-20 US US11/311,632 patent/US20060292133A1/en not_active Abandoned
2006
- 2006-06-29 US US11/478,545 patent/US20070141039A1/en not_active Abandoned
2007
- 2007-01-29 US US11/699,115 patent/US20080057109A1/en not_active Abandoned
2008
- 2008-05-19 US US12/123,052 patent/US20080311080A1/en not_active Abandoned
2009
- 2009-06-05 US US12/479,364 patent/US20100112003A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1688481A1 (en)	2006-08-09
CN101744841B (zh)	2013-05-15
NO20013429D0 (no)	2001-07-10
JP4706016B2 (ja)	2011-06-22
AU3071600A (en)	2000-08-01
US20050214272A1 (en)	2005-09-29
IL144185A0 (en)	2002-05-23
HK1044964A1 (en)	2002-11-08
MXPA01007152A (es)	2003-04-02
TR200102058T2 (tr)	2001-12-21
BRPI0007481B1 (pt)	2015-12-15
ATE326525T1 (de)	2006-06-15
EP1141235A2 (en)	2001-10-10
WO2000042168A2 (en)	2000-07-20
DK1143985T3 (da)	2007-11-19
US20030170217A1 (en)	2003-09-11
US20030166257A1 (en)	2003-09-04
US20070141039A1 (en)	2007-06-21
US20080057109A1 (en)	2008-03-06
US20060292133A1 (en)	2006-12-28
US20080311080A1 (en)	2008-12-18
WO2000041707A2 (en)	2000-07-20
BRPI0007481A (pt)	2002-04-09
NO20013467D0 (no)	2001-07-12
US20020006432A1 (en)	2002-01-17
WO2000041707A3 (en)	2001-09-27
BR0007550A (pt)	2001-10-30
AU3071700A (en)	2000-08-01
US20060002908A1 (en)	2006-01-05
RU2001119046A (ru)	2003-06-20
CA2359334C (en)	2011-03-22
EP1143985A2 (en)	2001-10-17
CN101744841A (zh)	2010-06-23
IE20000033A1 (en)	2000-08-09
AU779405B2 (en)	2005-01-20
ATE326012T1 (de)	2006-06-15
IL144185A (en)	2009-05-04
CN1338940A (zh)	2002-03-06
EP1143985B1 (en)	2007-07-25
NZ529353A (en)	2005-06-24
DE60028003D1 (de)	2006-06-22
EP1145001A2 (en)	2001-10-17
IL144184A0 (en)	2002-05-23
NO20013429L (no)	2001-08-27
CA2360243A1 (en)	2000-07-20
CN100552016C (zh)	2009-10-21
US20050074441A1 (en)	2005-04-07
CA2724287A1 (en)	2000-07-20
WO2000042168A3 (en)	2000-11-16
ATE367820T1 (de)	2007-08-15
JP2004502633A (ja)	2004-01-29
CN1342196A (zh)	2002-03-27
TR200102059T2 (tr)	2002-02-21
DE60035670D1 (de)	2007-09-06
EP1141235B1 (en)	2006-05-17
EP1145001B1 (en)	2006-05-10
DK1141235T3 (da)	2006-09-18
DE60035670T2 (de)	2008-04-30
US20030215467A1 (en)	2003-11-20
US20050084482A1 (en)	2005-04-21
ID30449A (id)	2001-12-06
RU2308483C2 (ru)	2007-10-20
CA2359334A1 (en)	2000-07-20
WO2000042429A2 (en)	2000-07-20
ES2290008T3 (es)	2008-02-16
ES2265331T3 (es)	2007-02-16
EP1143985A3 (en)	2002-08-28
BRPI0007481B8 (pt)	2021-07-06
JP2002534113A (ja)	2002-10-15
PT1141235E (pt)	2006-10-31
AU3071500A (en)	2000-08-01
US20100112003A1 (en)	2010-05-06
DE60027866D1 (de)	2006-06-14
NO20013467L (no)	2001-09-14
NZ530273A (en)	2005-04-29
MXPA01007144A (es)	2002-04-24
CN1245994C (zh)	2006-03-22
WO2000042429A3 (en)	2001-10-11
RU2279282C2 (ru)	2006-07-10
US7195906B2 (en)	2007-03-27
ID29150A (id)	2001-08-02
DE60028003T2 (de)	2007-04-12
HK1044964B (zh)	2010-01-15

Publication	Publication Date	Title
NO327792B1 (no)	2009-09-28	Bifidobakteriumstamme, formulering omfattende nevnte stamme, og anvendelse derav i matprodukter eller medikamenter ved behandling av sykdom.
US20030092163A1 (en)	2003-05-15	Probiotic bifidobacterium strains
NZ543584A (en)	2008-04-30	Probiotic lactobacillus salivarius strains AH102 (NCIMB 41044)
ZA200105617B (en)	2002-10-22	Bifidobacterium in the treatment of inflammatory disease.
IE20000034A1 (en)	2000-08-09	Bifidobacterium in the treatment of Inflammatory Disease
Moussavi	2012	Comparative analysis of the viability and functional performance of mono-and multi-species probiotic cultures in a non-dairy food matrix
ZA200400555B (en)	2004-09-21	Probiotic bifidobacterium strains.
IE20020626A1 (en)	2003-03-19	Probiotic Bifidobacterium strains

Legal Events

Date	Code	Title	Description
2020-02-10	MK1K	Patent expired